Trondheim

• Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting
  2022-501874-21-00 6 2020-12-15 Takotsubo syndrome
• Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Recruiting
  2024-510716-71-00 5 2020-10-21 Multiple Sclerosis
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting
  2022-501456-28-00 5 2020-07-20 atypical teratoid/rhabdoid tumours (ATRT)
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 10 2020-07-13 Acute Lymphoblastic Leukaemia
• The BASIC study Recruiting
  2024-515166-14-00 5 2019-11-01 Chronic cluster headache
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - The INSTAR study Recruiting
  2024-515350-25-01 6 2019-04-12 Acute wheezing/bronchiolitis
• A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting
  2023-504880-18-00 9 2018-04-18 Neuroblastoma (NBL)
• Paediatric Hepatic International Tumour Trial Recruiting
  2024-516110-38-00 5 2018-03-06 Hepatoblastoma and Hepatocellular Carcinoma
• The Norwegian Antibiotics for Pneumonia in Children (NAPIC) Study Recruiting
  2024-512001-39-01 6 2018-02-01 Lower respiratory tract infection
• Nordic Pancreatic Cancer Trial (NORPACT) – 1 Recruiting
  2024-517719-65-00 4 2017-02-01 Resectable pancreatic head cancer
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 10 2015-05-05 Recurrent and Primary Refractory Ewing Sarcoma
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting
  2024-515626-92-00 4 2013-10-18 recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
• NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years Recruiting
  2024-518254-16-00 5 2013-03-01 Acute Myeloid Leukemia (Pediatric 0-18 years)
• Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended recruitment
  2024-519530-24-00 5 2025-10-31 Overweight and obesity
• A Study to Find Out How Safe and Effective AZD0780 Is for Adults with High 'Bad' Cholesterol from an Inherited Condition Ended recruitment
  2025-520520-17-00 5 2025-09-05 Heterozygous familial hypercholesterolaemia
• PErsonalized TREatment of high-risk MAmmary Cancer - the PETREMAC trial Ended recruitment
  2024-519364-40-00 4 2024-11-29 Breast cancer
• Prevention of cardiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial (PRADA-II) Ended recruitment
  2024-515323-11-00 4 2024-11-13 Heart Failure
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves … Ended recruitment
  2022-502640-12-01 9 2024-09-27 Non-small cell lung cancer (NSCLC)
• RElapse from Mrd Negativity As iNdication for Treatment Ended recruitment
  2023-510215-18-00 10 2024-09-26 Multiple myeloma

Showing 97–120 of 186 trials